Genmab A/S operates as an international biotechnology company.
Pipeline and Product Candidates
The company has a pipeline of novel antibody-based products and product candidates designed to address unmet medical needs and improve treatment outcomes…
Analysis
Middle-of-the-road
Genmab A/S is a middle-of-the-road business: neither the economics nor the price stand out from the peer group. One caution: reported profits have recently run ahead of actual cash, which we track closely.
The price is fair. You pay 18.3× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 5% yearly growth; analysts expect 21%. The price, in other words, assumes less than the experts do.
The trajectory is tepid and the balance sheet is stretched. The company scores 12/20 on our value-creation score: creating some value. Analyst sentiment is cautious.
What to watch: Some accounting patterns deserve a closer look. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202340
100
2023202420252026
All-time high
100
Jun 2026
All-time low
37
Apr 2025
Average rank
66
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
62
11
9
3
Price/Earnings
21
47
17
10
Price/Book
45
42
19
8
Dividend Yield
1
1
1
1
Value (overall)
37
10
6
1
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.